The Place of Cannabinoids in the Treatment of Gynecological Pain.
Journal
Drugs
ISSN: 1179-1950
Titre abrégé: Drugs
Pays: New Zealand
ID NLM: 7600076
Informations de publication
Date de publication:
Nov 2023
Nov 2023
Historique:
accepted:
20
09
2023
medline:
4
12
2023
pubmed:
13
10
2023
entrez:
13
10
2023
Statut:
ppublish
Résumé
Cannabis sativa (L), a plant with an extensive history of medicinal usage across numerous cultures, has received increased attention over recent years for its therapeutic potential for gynecological disorders such as endometriosis, chronic pelvic pain, and primary dysmenorrhea, due at least in part to shortcomings with current management options. Despite this growing interest, cannabis inhabits an unusual position in the modern medical pharmacopoeia, being a legal medicine, legal recreational drug, and an illicit drug, depending on jurisdiction. To date, the majority of studies investigating cannabis use have found that most people are using illicit cannabis, with numerous obstacles to medical cannabis adoption having been identified, including outdated drug-driving laws, workplace drug testing policies, the cost of quality-assured medical cannabis products, a lack of cannabis education for healthcare professionals, and significant and persistent stigma. Although currently lacking robust clinical trial data, a growing evidence base of retrospective data, cohort studies, and surveys does support potential use in gynecological pain conditions, with most evidence focusing on endometriosis. Cannabis consumers report substantial reductions in pelvic pain, as well as common comorbid symptoms such as gastrointestinal disturbances, mood disorders such as anxiety and depression, and poor sleep. Substitution effects were reported, with >50% reduction or cessation in opioid and/or non-opioid analgesics being the most common. However, a substantial minority report not disclosing cannabis consumption to their health professional. Therefore, while such deprescribing trends are potentially beneficial, the importance of medical supervision during this process is paramount given the possibility for withdrawal symptoms. Cannabis, whether purchased illicitly, or obtained through legal means, is commonly used by those with chronic pelvic pain, especially people with endometriosis. People report several benefits from using cannabis, including being able to reduce their normal medications including opioid based painkillers, but often don’t tell their health professional about this. This could lead to issues with withdrawal symptoms, so clinicians should be aware of the high prevalence of use of cannabis in this population.
Autres résumés
Type: plain-language-summary
(eng)
Cannabis, whether purchased illicitly, or obtained through legal means, is commonly used by those with chronic pelvic pain, especially people with endometriosis. People report several benefits from using cannabis, including being able to reduce their normal medications including opioid based painkillers, but often don’t tell their health professional about this. This could lead to issues with withdrawal symptoms, so clinicians should be aware of the high prevalence of use of cannabis in this population.
Identifiants
pubmed: 37831340
doi: 10.1007/s40265-023-01951-z
pii: 10.1007/s40265-023-01951-z
pmc: PMC10693518
doi:
Substances chimiques
Cannabinoids
0
Medical Marijuana
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1571-1579Informations de copyright
© 2023. The Author(s).
Références
Gynecological diseases - Level 3 cause. Institute for Health Metrics and Evaluation. 2019; https://www.healthdata.org/results/gbd_summaries/2019/gynecological-diseases-level-3-cause#:~:text=Summary%20Gynaecological%20diseases%20caused%20a,with%20gynaecological%20diseases%20in%202019 . Accessed 3 June 2023.
Armour M, et al. The prevalence and academic impact of dysmenorrhea in 21,573 young women: a systematic review and meta-analysis. J Womens Health (Larchmt). 2019;28(8):1161–71.
pubmed: 31170024
doi: 10.1089/jwh.2018.7615
Coco AS. Primary dysmenorrhea. Am Fam Physician. 1999;60(2):489–96.
pubmed: 10465224
Proctor M, Farquhar C. Diagnosis and management of dysmenorrhoea. BMJ. 2006;332(7550):1134–8.
pubmed: 16690671
pmcid: 1459624
doi: 10.1136/bmj.332.7550.1134
Dawood MY. Primary dysmenorrhea: advances in pathogenesis and management. Obstet Gynecol. 2006;108(2):428–41.
pubmed: 16880317
doi: 10.1097/01.AOG.0000230214.26638.0c
Morrow C, Naumburg EH. Dysmenorrhea. Prim Care. 2009;36(1):19–32 (vii).
pubmed: 19231600
doi: 10.1016/j.pop.2008.10.004
Zahradnik HP, Hanjalic-Beck A, Groth K. Nonsteroidal anti-inflammatory drugs and hormonal contraceptives for pain relief from dysmenorrhea: a review. Contraception. 2010;81(3):185–96.
pubmed: 20159173
doi: 10.1016/j.contraception.2009.09.014
Armour M, et al. The prevalence and educational impact of pelvic and menstrual pain in Australia: a National Online Survey of 4202 Young Women Aged 13–25 Years. J Pediatr Adolesc Gynecol. 2020;33(5):511–8.
pubmed: 32544516
doi: 10.1016/j.jpag.2020.06.007
Parker MA, Sneddon AE, Arbon P. The menstrual disorder of teenagers (MDOT) study: determining typical menstrual patterns and menstrual disturbance in a large population-based study of Australian teenagers. BJOG. 2010;117(2):185–92.
pubmed: 19874294
doi: 10.1111/j.1471-0528.2009.02407.x
Schoep ME, et al. Productivity loss due to menstruation-related symptoms: a nationwide cross-sectional survey among 32 748 women. BMJ Open. 2019;9(6): e026186.
pubmed: 31248919
pmcid: 6597634
doi: 10.1136/bmjopen-2018-026186
Holmes K, et al. Adolescent Menstrual Health Literacy in Low, Middle and High-Income Countries: A Narrative Review. Int J Environ Res Public Health. 2021;18(5):2260.
pubmed: 33668788
pmcid: 7956698
doi: 10.3390/ijerph18052260
Armour M, et al. Menstrual Health Literacy and Management Strategies in Young Women in Australia: a National Online Survey of Young Women Aged 13–25 Years. J Pediatr Adolesc Gynecol. 2021;34(2):135–43.
pubmed: 33188935
doi: 10.1016/j.jpag.2020.11.007
Sinclair J, et al. Should I inhale?;Perceptions, barriers, and drivers for medicinal cannabis use amongst australian women with primary dysmenorrhoea: a qualitative study. Int J Environ Res Public Health. 2022;19(3):1536.
pubmed: 35162564
pmcid: 8835209
doi: 10.3390/ijerph19031536
Howard F, et al. Pelvic pain: diagnosis and management. Philadelphia: Lippincott Williams and Wilkins; 2000.
Hawkey A, et al. “A day-to-day struggle”: A comparative qualitative study on experiences of women with endometriosis and chronic pelvic pain. Femin Psychol. 2022;32:482–500.
doi: 10.1177/09593535221083846
Moradi M, et al. Impact of endometriosis on women’s lives: a qualitative study. BMC Womens Health. 2014;14(1):123.
pubmed: 25280500
pmcid: 4287196
doi: 10.1186/1472-6874-14-123
Armour M, et al. Endometriosis and the workplace: lessons from Australia’s response to COVID-19. Aust N Z J Obstet Gynaecol. 2022;62(1):164–7.
pubmed: 34811735
doi: 10.1111/ajo.13458
Lamvu G, et al. Chronic pelvic pain in women: a review. JAMA. 2021;325(23):2381–91.
pubmed: 34128995
doi: 10.1001/jama.2021.2631
Armour M, et al. Endometriosis and chronic pelvic pain have similar impact on women, but time to diagnosis is decreasing: an Australian survey. Sci Rep. 2020;10(1):16253.
pubmed: 33004965
pmcid: 7529759
doi: 10.1038/s41598-020-73389-2
Ahangari A. Prevalence of chronic pelvic pain among women: an updated review. Pain Physician. 2014;17(2):E141–7.
pubmed: 24658485
doi: 10.36076/ppj.2014/17/E141
Liang AL, Gingher EL, Coleman JS. Medical cannabis for gynecologic pain conditions: a systematic review. Obstet Gynecol. 2022;139(2):287–96.
pubmed: 35104069
doi: 10.1097/AOG.0000000000004656
Armour M, et al. The cost of illness and economic burden of endometriosis and chronic pelvic pain in Australia: A national online survey. PLoS ONE. 2019;14(10): e0223316.
pubmed: 31600241
pmcid: 6786587
doi: 10.1371/journal.pone.0223316
Hickey M, Ballard K, Farquhar C. Endometriosis. BMJ. 2014;348: g1752.
pubmed: 24647161
doi: 10.1136/bmj.g1752
Armour M, et al. Self-care strategies and sources of knowledge on menstruation in 12,526 young women with dysmenorrhea: A systematic review and meta-analysis. PLoS ONE. 2019;14(7): e0220103.
pubmed: 31339951
pmcid: 6655766
doi: 10.1371/journal.pone.0220103
Evans S, et al. Treatment use and satisfaction in Australian women with endometriosis: a mixed-methods study. Intern Med J. 2022;52(12):2096–106.
pubmed: 34396651
doi: 10.1111/imj.15494
Sinaii N, et al. Treatment utilization for endometriosis symptoms: a cross-sectional survey study of lifetime experience. Fertil Steril. 2007;87(6):1277–86.
pubmed: 17296195
doi: 10.1016/j.fertnstert.2006.11.051
As-Sanie S, et al. Healthcare utilization and cost burden among women with endometriosis by opioid prescription status in the first year after diagnosis: a retrospective claims database analysis. J Med Econ. 2020;23:1–7.
doi: 10.1080/13696998.2019.1707212
Chiuve SE, et al. Chronic opioid use and complication risks in women with endometriosis: a cohort study in US administrative claims. Pharmacoepidemiol Drug Saf. 2021;30:787–96.
pubmed: 33611812
pmcid: 8251707
doi: 10.1002/pds.5209
Armour M, et al. Lessons from implementing the Australian National Action Plan for Endometriosis. Reproduction and Fertility, 2022: p. RAF-22-0003.
Roman H, et al. Long-term risk of repeated surgeries in women managed for endometriosis: a 1,092 patient-series. Fertil Steril. 2023;120:870–9.
pubmed: 37225069
doi: 10.1016/j.fertnstert.2023.05.156
Horne AW, et al. Top ten endometriosis research priorities in the UK and Ireland. Lancet. 2017;389(10085):2191–2.
pubmed: 28528751
doi: 10.1016/S0140-6736(17)31344-2
Rogers PA, et al. Research priorities for endometriosis. Reprod Sci. 2017;24(2):202–26.
pubmed: 27368878
doi: 10.1177/1933719116654991
Armour M, et al. Endometriosis research priorities in Australia. Aust N Z J Obstet Gynaecol. 2023;63:594–8.
pubmed: 37226362
doi: 10.1111/ajo.13699
Russo EB. History of cannabis and its preparations in saga, science, and sobriquet. Chem Biodivers. 2007;4(8):1614–48.
pubmed: 17712811
doi: 10.1002/cbdv.200790144
Clarke R, Merlin MD. Cannabis evolution and ethnobotany. Berkeley: University of California Press; 2013.
Zuardi AW. History of cannabis as a medicine: a review. Rev Bras Psiquiatr. 2006;28(2):153–7.
pubmed: 16810401
doi: 10.1590/S1516-44462006000200015
Russo EB. Cannabis treatments in obstetrics and gynecology: a historical review. J Cannabis Therap. 2002;2(3–4):5–35.
doi: 10.1300/J175v02n03_02
Touwn M. The religious and medicinal uses of Cannabis in China, india and Tibet. J Psychoactive Drugs. 1981;13:23–34.
doi: 10.1080/02791072.1981.10471447
Churchill F. Essays on the puerperal fever and other diseases peculiar to women. London: Sydenham Society; 1849.
Christison A. On the natural history, action, and uses of Indian Hemp. Mon J Med Sci. 1851;4(19):26–45.
Willis I. Cannabis indica. Boston Med Surg J. 1859;61:173–8.
doi: 10.1056/NEJM185909290610902
Brown J. Cannabis indica; A valuable remedy in menorrhagia. BMJ. 1883;1:1002.
Hare H. Clinical and physiological notes on the action of Cannabis indica. Therapeutic Gazette. 1887;2:225–8.
Clendinning J. Observation on the medicinal properties of Cannabis sativa from India. Medico-Chirurg Trans. 1843;26:188–210.
doi: 10.1177/095952874302600116
Russo E. The pharmacological history of cannabis. In: Pertwee R, editor. Handbook of Cannabis. Oxford: Oxford University Press; 2016. p. 23–43.
Pereira P. The elements of materia medica and therapeutics. Philadelphia: Lea & Blanchard; 1843.
Fankhauser M. History of cannabis in Western Medicine. In: Grotenhermen F, Russo E, editors. Cannabis and cannabinoids: pharmacology, toxicology, and therapeutic potential. New York: Hawthorn Integrative Healing Press; 2002. p. 1–439.
Bridgeman MB, Abazia DT. Medicinal Cannabis: History, Pharmacology, And Implications for the Acute Care Setting. P T. 2017;42(3):180–8.
pubmed: 28250701
pmcid: 5312634
Sinclair J, Adams C, Thurgood G-R, Davidson M, Armour M, Sarris J. Cannabidiol (CBD) oil: Rehashing the research, roles and regulations in Australia. Austra J Herb Naturopathic Med. 2020;32:54–60.
Duke S. Cannabis captiva: freeing the world from marijuana prohibition. Georgetown J Int Affairs. 2010;11:83–90.
Gaoni Y, Mechoulam R. Isolation, structure and partial synthesis of an active constituent of hashish. J Am Chem Soc. 1964;86:1646–7.
doi: 10.1021/ja01062a046
Crocq MA. History of cannabis and the endocannabinoid system. Dialogues Clin Neurosci. 2020;22(3):223–8.
pubmed: 33162765
pmcid: 7605027
doi: 10.31887/DCNS.2020.22.3/mcrocq
Castillo A, et al. The neuroprotective effect of cannabidiol in an in vitro model of newborn hypoxic-ischemic brain damage in mice is mediated by CB(2) and adenosine receptors. Neurobiol Dis. 2010;37(2):434–40.
pubmed: 19900555
doi: 10.1016/j.nbd.2009.10.023
Jones NA, et al. Cannabidiol displays antiepileptiform and antiseizure properties in vitro and in vivo. J Pharmacol Exp Ther. 2010;332(2):569–77.
pubmed: 19906779
pmcid: 2819831
doi: 10.1124/jpet.109.159145
Bergamaschi MM, et al. Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-naive social phobia patients. Neuropsychopharmacology. 2011;36(6):1219–26.
pubmed: 21307846
pmcid: 3079847
doi: 10.1038/npp.2011.6
Zanelati TV, et al. Antidepressant-like effects of cannabidiol in mice: possible involvement of 5-HT1A receptors. Br J Pharmacol. 2010;159(1):122–8.
pubmed: 20002102
doi: 10.1111/j.1476-5381.2009.00521.x
Mukhopadhyay P, et al. Cannabidiol protects against hepatic ischemia/reperfusion injury by attenuating inflammatory signaling and response, oxidative/nitrative stress, and cell death. Free Radic Biol Med. 2011;50(10):1368–81.
pubmed: 21362471
pmcid: 3081988
doi: 10.1016/j.freeradbiomed.2011.02.021
Atalay S, Jarocka-Karpowicz I, Skrzydlewska E. Antioxidative and anti-inflammatory properties of cannabidiol. Antioxidants (Basel). 2019;9(1):21.
pubmed: 31881765
doi: 10.3390/antiox9010021
Rahn EJ, Hohmann AG. Cannabinoids as pharmacotherapies for neuropathic pain: from the bench to the bedside. Neurotherapeutics. 2009;6(4):713–37.
pubmed: 19789075
pmcid: 2755639
doi: 10.1016/j.nurt.2009.08.002
Haney M, et al. Dronabinol and marijuana in HIV(+) marijuana smokers: acute effects on caloric intake and mood. Psychopharmacology. 2005;181(1):170–8.
pubmed: 15778874
doi: 10.1007/s00213-005-2242-2
Kavia RB, et al. Randomized controlled trial of Sativex to treat detrusor overactivity in multiple sclerosis. Mult Scler. 2010;16(11):1349–59.
pubmed: 20829244
doi: 10.1177/1352458510378020
Russo EB. Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. Br J Pharmacol. 2011;163(7):1344–64.
pubmed: 21749363
pmcid: 3165946
doi: 10.1111/j.1476-5381.2011.01238.x
Hanus LO, et al. Phytocannabinoids: a unified critical inventory. Nat Prod Rep. 2016;33(12):1357–92.
pubmed: 27722705
doi: 10.1039/C6NP00074F
Pacher P, Kunos G. Modulating the endocannabinoid system in human health and disease–successes and failures. FEBS J. 2013;280(9):1918–43.
pubmed: 23551849
pmcid: 3684164
doi: 10.1111/febs.12260
McPartland JM, Guy GW, Di Marzo V. Care and feeding of the endocannabinoid system: a systematic review of potential clinical interventions that upregulate the endocannabinoid system. PLoS ONE. 2014;9(3): e89566.
pubmed: 24622769
pmcid: 3951193
doi: 10.1371/journal.pone.0089566
Henry RJ, et al. For whom the endocannabinoid tolls: Modulation of innate immune function and implications for psychiatric disorders. Prog Neuropsychopharmacol Biol Psychiatry. 2016;64:167–80.
pubmed: 25794989
doi: 10.1016/j.pnpbp.2015.03.006
Walker OS, Holloway AC, Raha S. The role of the endocannabinoid system in female reproductive tissues. J Ovarian Res. 2019;12(1):3.
pubmed: 30646937
pmcid: 6332911
doi: 10.1186/s13048-018-0478-9
Gentilini D, et al. Endocannabinoid system regulates migration of endometrial stromal cells via cannabinoid receptor 1 through the activation of PI3K and ERK1/2 pathways. Fertil Steril. 2010;93(8):2588–93.
pubmed: 20303477
doi: 10.1016/j.fertnstert.2010.02.006
Di Blasio AM, Vignali M, Gentilini D. The endocannabinoid pathway and the female reproductive organs. J Mol Endocrinol. 2013;50(1):R1-9.
pubmed: 23178290
doi: 10.1530/JME-12-0182
Sanchez AM, et al. Elevated systemic levels of endocannabinoids and related mediators across the menstrual cycle in women with endometriosis. Reprod Sci. 2016;23(8):1071–9.
pubmed: 26887427
doi: 10.1177/1933719116630414
Dmitrieva N, et al. Endocannabinoid involvement in endometriosis. Pain. 2010;151(3):703–10.
pubmed: 20833475
pmcid: 2972363
doi: 10.1016/j.pain.2010.08.037
Sanchez AM, et al. The molecular connections between the cannabinoid system and endometriosis. Mol Hum Reprod. 2012;18(12):563–71.
pubmed: 22923487
doi: 10.1093/molehr/gas037
Bouaziz J, et al. The clinical significance of endocannabinoids in endometriosis pain management. Cannabis Cannabinoid Res. 2017;2(1):72–80.
pubmed: 28861506
pmcid: 5436335
doi: 10.1089/can.2016.0035
Maia J, et al. The fundamental role of the endocannabinoid system in endometrium and placenta: implications in pathophysiological aspects of uterine and pregnancy disorders. Hum Reprod Update. 2020;26(4):586–602.
pubmed: 32347309
pmcid: 7317288
doi: 10.1093/humupd/dmaa005
Shen X, et al. Expression of cannabinoid receptors in myometrium and its correlation with dysmenorrhea in adenomyosis. Reprod Sci. 2019;26(12):1618–25.
pubmed: 30832539
doi: 10.1177/1933719119833483
Piomelli D, Sasso O. Peripheral gating of pain signals by endogenous lipid mediators. Nat Neurosci. 2014;17(2):164–74.
pubmed: 24473264
pmcid: 4020413
doi: 10.1038/nn.3612
Rice AS. Cannabinoids and pain. Curr Opin Investig Drugs. 2001;2(3):399–414.
pubmed: 11575713
Hill KP, et al. Cannabis and pain: a clinical review. Cannabis Cannabinoid Res. 2017;2(1):96–104.
pubmed: 28861509
pmcid: 5549367
doi: 10.1089/can.2017.0017
Ahluwalia J, et al. Cannabinoid 1 receptors are expressed in nociceptive primary sensory neurons. Neuroscience. 2000;100(4):685–8.
pubmed: 11036202
doi: 10.1016/S0306-4522(00)00389-4
Milligan AL, Szabo-Pardi TA, Burton MD. Cannabinoid receptor type 1 and its role as an analgesic: an opioid alternative? J Dual Diagn. 2020;16(1):106–19.
pubmed: 31596190
doi: 10.1080/15504263.2019.1668100
Marcu I, Gee A, Lynn B. Cannabinoids and chronic pelvic pain in women: focus on endometriosis. J Endomet aPelvic Pain Disord. 2021;13(3):155–65.
doi: 10.1177/22840265211011277
Guindon J, Hohmann AG. The endocannabinoid system and pain. CNS Neurol Disord Drug Targets. 2009;8(6):403–21.
pubmed: 19839937
pmcid: 2834283
doi: 10.2174/187152709789824660
Ibrahim MM, et al. CB2 cannabinoid receptor activation produces antinociception by stimulating peripheral release of endogenous opioids. Proc Natl Acad Sci U S A. 2005;102(8):3093–8.
pubmed: 15705714
pmcid: 549497
doi: 10.1073/pnas.0409888102
Manzanares J, Julian M, Carrascosa A. Role of the cannabinoid system in pain control and therapeutic implications for the management of acute and chronic pain episodes. Curr Neuropharmacol. 2006;4(3):239–57.
pubmed: 18615144
pmcid: 2430692
doi: 10.2174/157015906778019527
Ibrahim MM, et al. Activation of CB2 cannabinoid receptors by AM1241 inhibits experimental neuropathic pain: pain inhibition by receptors not present in the CNS. Proc Natl Acad Sci U S A. 2003;100(18):10529–33.
pubmed: 12917492
pmcid: 193595
doi: 10.1073/pnas.1834309100
Muller C, Morales P, Reggio PH. Cannabinoid ligands targeting TRP channels. Front Mol Neurosci. 2018;11:487.
pubmed: 30697147
doi: 10.3389/fnmol.2018.00487
Pisanti S, et al. Antiangiogenic activity of the endocannabinoid anandamide: correlation to its tumor-suppressor efficacy. J Cell Physiol. 2007;211(2):495–503.
pubmed: 17192847
doi: 10.1002/jcp.20954
Leconte M, et al. Antiproliferative effects of cannabinoid agonists on deep infiltrating endometriosis. Am J Pathol. 2010;177(6):2963–70.
pubmed: 21057002
pmcid: 2993285
doi: 10.2353/ajpath.2010.100375
Clarke H, Fitzcharles M. The evolving culture of medical cannabis in Canada for the management of chronic pain. Front Pharmacol. 2023;14:1153584.
pubmed: 37089954
pmcid: 10119390
doi: 10.3389/fphar.2023.1153584
Perkins D, et al. Medicinal cannabis and driving: the intersection of health and road safety policy. Int J Drug Policy. 2021;97: 103307.
pubmed: 34107448
doi: 10.1016/j.drugpo.2021.103307
Armour M, Sinclair J. Cannabis for endometriosis-related pain and symptoms: It’s high time that we see this as a legitimate treatment. Aust N Z J Obstet Gynaecol. 2023;63(1):118–20.
pubmed: 36691911
doi: 10.1111/ajo.13642
Carrubba AR, et al. Use of cannabis for self-management of chronic pelvic pain. J Womens Health (Larchmt). 2021;30(9):1344–51.
pubmed: 33252316
doi: 10.1089/jwh.2020.8737
Armour M, et al. Self-management strategies amongst Australian women with endometriosis: a national online survey. BMC Complement Altern Med. 2019;19(1):17.
pubmed: 30646891
pmcid: 6332532
doi: 10.1186/s12906-019-2431-x
Sinclair J, Smith CA, Abbott J, Chalmers KJ, Pate DW, Armour M. Cannabis use, a self-management strategy among australian women with endometriosis: results from a National Online Survey. J Obstet Gynaecol Can. 2020;42:256–61. https://doi.org/10.1016/j.jogc.2019.08.033 .
Sinclair J, et al. Effects of cannabis ingestion on endometriosis-associated pelvic pain and related symptoms. PLoS ONE. 2021;16(10): e0258940.
pubmed: 34699540
pmcid: 8547625
doi: 10.1371/journal.pone.0258940
MacCallum CA, Russo EB. Practical considerations in medical cannabis administration and dosing. Eur J Intern Med. 2018;49:12–9.
pubmed: 29307505
doi: 10.1016/j.ejim.2018.01.004
Armour M, et al. Endometriosis and cannabis consumption during the COVID-19 pandemic: an international cross-sectional survey. Cannabis Cannabinoid Res. 2022;7(4):473–81.
pubmed: 35089093
pmcid: 9418353
doi: 10.1089/can.2021.0162
Armour M, et al. Illicit cannabis usage as a management strategy in New Zealand women with endometriosis: an online survey. J Womens Health (Larchmt). 2021;30(10):1485–92.
pubmed: 33275491
doi: 10.1089/jwh.2020.8668
Sinclair J, et al. Cannabis use for endometriosis: clinical and legal challenges in Australia and New Zealand. Cannabis Cannabinoid Res. 2022;7(4):464–72.
pubmed: 34978929
pmcid: 9418363
doi: 10.1089/can.2021.0116
MacCallum CA, Lo LA, Boivin M. “Is medical cannabis safe for my patients?” A practical review of cannabis safety considerations. Eur J Intern Med. 2021;89:10–8.
pubmed: 34083092
doi: 10.1016/j.ejim.2021.05.002
Petursson H. The benzodiazepine withdrawal syndrome. Addiction. 1994;89(11):1455–9.
pubmed: 7841856
doi: 10.1111/j.1360-0443.1994.tb03743.x
Pergolizzi JV Jr, Raffa RB, Rosenblatt MH. Opioid withdrawal symptoms, a consequence of chronic opioid use and opioid use disorder: Current understanding and approaches to management. J Clin Pharm Ther. 2020;45(5):892–903.
pubmed: 31986228
doi: 10.1111/jcpt.13114
Reid M. A qualitative review of cannabis stigmas at the twilight of prohibition. J Cannabis Res. 2020;2(1):46.
pubmed: 33526147
pmcid: 7819345
doi: 10.1186/s42238-020-00056-8
Troup LJ, et al. Perceived stigma of patients undergoing treatment with cannabis-based medicinal products. Int J Environ Res Public Health. 2022;19(12):7499.
pubmed: 35742748
pmcid: 9223559
doi: 10.3390/ijerph19127499
Bottorff JL, et al. Perceptions of cannabis as a stigmatized medicine: a qualitative descriptive study. Harm Reduct J. 2013;10:2.
pubmed: 23414118
pmcid: 3584982
doi: 10.1186/1477-7517-10-2
Sinclair J, et al. “Should I Inhale?”-perceptions, barriers, and drivers for medicinal cannabis use amongst Australian women with primary dysmenorrhoea: a qualitative study. Int J Environ Res Public Health. 2022;19(3):1536.
pubmed: 35162564
pmcid: 8835209
doi: 10.3390/ijerph19031536
Isaac S, Saini B, Chaar BB. The Role of Medicinal Cannabis in Clinical Therapy: Pharmacists’ Perspectives. PLoS ONE. 2016;11(5): e0155113.
pubmed: 27171490
pmcid: 4865212
doi: 10.1371/journal.pone.0155113
Sabmeethavorn Q, Bonomo YA, Hallinan CM. Pharmacists’ perceptions and experiences of medicinal cannabis dispensing: a narrative review with a systematic approach. Int J Pharm Pract. 2022;30(3):204–14.
pubmed: 35225341
doi: 10.1093/ijpp/riac005
Melnikov S, et al. The effect of attitudes, subjective norms and stigma on health-care providers’ intention to recommend medicinal cannabis to patients. Int J Nurs Pract. 2021;27(1): e12836.
pubmed: 32237017
doi: 10.1111/ijn.12836
Clobes T, Palmier LA, Gagnon M, Klaiman C, Arellano M. The impact of education on attitudes toward medical cannabis. PEC Innovation. 2022;1:1–5.
Young K, Fisher J, Kirkman M. Women’s experiences of endometriosis: a systematic review and synthesis of qualitative research. J Fam Plann Reprod Health Care. 2015;41(3):225–34.
pubmed: 25183531
doi: 10.1136/jfprhc-2013-100853
Young K, Fisher J, Kirkman M. Clinicians’ perceptions of women’s experiences of endometriosis and of psychosocial care for endometriosis. Aust N Z J Obstet Gynaecol. 2017;57(1):87–92.
pubmed: 28251627
doi: 10.1111/ajo.12571
Howard J, Osborne J. Cannabis and work: need for more research. Am J Ind Med. 2020;63(11):963–72.
pubmed: 32797692
doi: 10.1002/ajim.23170
McCartney D, et al. Determining the magnitude and duration of acute Delta(9)-tetrahydrocannabinol (Delta(9)-THC)-induced driving and cognitive impairment: a systematic and meta-analytic review. Neurosci Biobehav Rev. 2021;126:175–93.
pubmed: 33497784
doi: 10.1016/j.neubiorev.2021.01.003
Therapeutic Goods Order No. 93 (Standard for Medicinal Cannabis). Australian Federal Government. Department of Health: Canberra, ACT Australia; 2017.
Upton R, ElSohly M, Romm A, Russo E, Sexton M, editors. Cannabis inflorescence. Scotts Valley: American Herbal Pharmacopoeia; 2013. p. 55.